Incyte Corporation drugs

7 results

  • jakafi - ruxolitinib tablet

    (Ruxolitinib)
    Incyte Corporation
    Jakafi treats intermediate or high-risk myelofibrosis and polycythemia vera (in adults intolerant of or unresponsive to hydroxyurea). Also indicated for steroid-refractory acute and chronic graft-versus-host disease in adults and pediatric patients 12 and older.
    Medication Details
    Drug Interactions

  • monjuvi

    (Tafasitamab-Cxix)
    Incyte Corporation
    Monjuvi (tafasitamab), combined with lenalidomide, treats adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL from low-grade lymphoma, who are ineligible for autologous stem cell transplant. Approved under accelerated approval based on overall response rate.
    Medication Details
    Drug Interactions

  • niktimvo - axatilimab - csfr injection

    (Axatilimab-Csfr)
    Incyte Corporation
    Niktimvo treats chronic graft-versus-host disease (cGVHD) in adults and pediatric patients weighing at least 40 kg, after at least two prior systemic therapies have failed.
    Medication Details
    Drug Interactions

  • opzelura - ruxolitinib cream

    (Ruxolitinib)
    Incyte Corporation
    Opzelura treats mild to moderate atopic dermatitis in adults and children 2+ years not adequately controlled by topical therapies, and nonsegmental vitiligo in adults and adolescents 12+ years. Not recommended with biologics, other JAK inhibitors, or potent immunosuppressants.
    Medication Details
    Drug Interactions

  • pemazyre - pemigatinib tablet

    (Pemigatinib)
    Incyte Corporation
    Pemazyre treats adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma with an FGFR2 fusion or rearrangement, and adults with relapsed or refractory myeloid/lymphoid neoplasms with FGFR1 rearrangement.
    Medication Details
    Drug Interactions

  • zynyz - retifanlimab - dlwr injection

    (Retifanlimab-Dlwr)
    Incyte Corporation
    ZYNYZ treats squamous cell carcinoma of the anal canal (SCAC) — with carboplatin and paclitaxel as first-line therapy, or as a single agent after platinum-based chemotherapy. Also indicated for metastatic or recurrent locally advanced Merkel cell carcinoma (MCC) in adults.
    Medication Details
    Drug Interactions